Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 5/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9924742 | 0.94 | MMP2 (0.61) | MMP2MMP3ALDH1A1HPGDMAOB | |
| Cyanate SCHEMBL27852686 | 0.94 | MMP2 (0.54) | MMP2MMP3ALDH1A1HPGDMAOB | |
| SCHEMBL17654333 | 0.86 | SLC6A2 (0.52) | MMP2MMP3ALDH1A1HPGDPOLB | |
| SCHEMBL11523862 | 0.85 | GRIA1 (0.48) | MMP2MMP3ALDH1A1HPGDPOLB | |
| SCHEMBL11523868 | 0.85 | GRIA1 (0.48) | MMP2MMP3ALDH1A1HPGDPOLB | |
| SCHEMBL123415 | 0.84 | MAPT (0.55) | ALDH1A1HPGDPOLBMAPTKDM4E | |
| SCHEMBL25484191 | 0.84 | LMNA (0.60) | MMP2MMP3ALDH1A1HPGDMAOB | |
| SCHEMBL8605326 | 0.84 | MMP2 (0.51) | MMP2MMP3ALDH1A1HPGDMAOB | |
| SCHEMBL29113764 | 0.84 | LMNA (0.60) | MMP2MMP3ALDH1A1HPGDMAOB | |
| SCHEMBL30102507 | 0.84 | LMNA (0.60) | MMP2MMP3ALDH1A1HPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. | 2022-01-27 | — | — | US | claimed |
| EP-3325444-B1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARM INC (US) | 2021-07-07 | — | — | EP | claimed |
| CN-107848972-B | Process for the preparation of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N' - (4- (2-methylpropyloxy) phenylmethyl) urea and its tartrate salt and polymorph C | 阿卡蒂亚药品公司 | 2021-06-18 | — | — | CN | claimed |
| EP-3828170-A1 | METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE | Livzon New North River Pharmaceutical Co., Ltd. (CN) | 2021-06-02 | — | — | EP | claimed |
| US-10934257-B2 | Method for preparing pimavanserin and tartrate thereof by using triphosgene | LIVZON NEW NORTH RIVER PHARMACEUTICAL CO., LTD. (CN) | 2021-03-02 | — | — | US | claimed |
| CN-108794351-B | Preparation method of pimavanserin key intermediate | 丽珠集团新北江制药股份有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-108947891-B | Method for safely preparing pimavanserin and tartrate thereof by using triphosgene | 丽珠集团新北江制药股份有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-109613163-B | Detection method for pimavanserin tartrate and impurities thereof | 丽珠集团新北江制药股份有限公司 | 2021-01-26 | — | — | CN | claimed |
| US-20200369612-A1 | Method for Safely Preparing Pimavanserin and Tartrate Thereof by Using Triphosgene | LIVZON NEW NORTH RIVER PHARMACEUTICAL CO., LTD. (CN) | 2020-11-26 | — | — | US | claimed |
| US-10597363-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C | ACADIA PHARMACEUTICALS INC. (US) | 2020-03-24 | — | — | US | claimed |
| WO-2020020064-A1 | METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE | 丽珠集团新北江制药股份有限公司 | 2020-01-30 | — | — | WO | claimed |
| CN-109613163-A | A kind of detection method of tartaric acid Mo Fanselin and its impurity | 丽珠集团新北江制药股份有限公司 | 2019-04-12 | — | — | CN | claimed |
| CN-109574951-A | A kind of preparation method of Febuxostat | 安徽省庆云医药股份有限公司 | 2019-04-05 | — | — | CN | claimed |
| US-20190047955-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM | ACADIA PHARMACEUTICALS INC. | 2019-02-14 | — | — | US | claimed |
| CN-108947891-A | The method for safely preparing a Mo Fanselin and its tartrate using triphosgene | 丽珠集团新北江制药股份有限公司 | 2018-12-07 | — | — | CN | claimed |
| US-20180208556-A1 | Method for Preparing Pimavanserin | SCI PHARMTECH, INC. (TW) | 2018-07-26 | — | — | US | claimed |
| EP-3351532-A1 | METHOD FOR PREPARING PIMAVANSERIN | SCI Pharmatech, Inc. (TW) | 2018-07-25 | — | — | EP | claimed |
| EP-3325444-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | Acadia Pharmaceuticals Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017015272-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARMACEUTICALS INC. (US) | 2017-01-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369612-A1 | Method for Safely Preparing Pimavanserin and Tartrate Thereof by Using Triphosgene | PNP, PIM1, TYMP | MMP2 3260/4885MMP3 3639/4885ALDH1A1 2068/4885 |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | NR3C2, NR2C2, CYP4A22 | MMP2 2038/4885MMP3 3109/4885ALDH1A1 3655/4885 |
| US-20180208556-A1 | Method for Preparing Pimavanserin | PIM1, ALKBH1, PIM3 | MMP2 2474/4885MMP3 2665/4885ALDH1A1 115/4885 |
| US-20220024871-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | NR3C2, NR2C2, CYP4A22 | MMP2 2083/4885MMP3 3139/4885ALDH1A1 3677/4885 |
| US-10597363-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C | NR3C2, CYP4A22, NR2C2 | MMP2 2290/4885MMP3 3350/4885ALDH1A1 3967/4885 |
| US-20190047955-A1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM | NR3C2, CYP4A22, NR2C2 | MMP2 1952/4885MMP3 2895/4885ALDH1A1 3676/4885 |
| US-10934257-B2 | Method for preparing pimavanserin and tartrate thereof by using triphosgene | PNP, TYMP, PIM1 | MMP2 3206/4885MMP3 3670/4885ALDH1A1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.